The pharmaceutical industry in India supplies over 50% of global demand for various vaccines and generic drugs. It is expected to grow at 22.4% annually to reach $55 billion by 2025. India accounts for 20% of global exports in generics. Exports stood at $17.27 billion in 2017-18 and are projected to reach $20 billion by 2020. The domestic market is expected to reach $27.9 billion by 2020, driven by growing healthcare needs and rising income levels. Indian companies are expanding globally through exports and overseas investments to boost sales and access new markets.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- India supplies over 50% of global demand for various vaccines and generic drugs. The pharmaceutical sector was valued at $33 billion in 2017 and is expected to reach $55 billion by 2022, growing at 22.4% CAGR.
- India accounts for 20% of global exports in generics. Pharmaceutical exports stood at $17.27 billion in 2017-18 and are expected to reach $20 billion by 2020.
- The domestic generics market is expected to reach $27.9 billion by 2020 and has immense growth potential. By 2024-25, the biotech industry is estimated to increase to $100 billion
Indian pharmaceutical industry is the third largest in terms of volume and provides over 50% of global demand for various vaccines, 40% of generic demand in US, and 25% of all medicine in UK. It is expected to grow at 22.4% annually to $55 billion by 2025. India accounts for 20% of global exports in generics with exports reaching $17.27 billion in 2017-18. The domestic market is expected to reach $27.9 billion by 2020 driven by increased healthcare spending and penetration of health insurance in India. The industry has immense potential for growth in generics, biotech and contract manufacturing segments.
Indian pharmaceutical industry supplies over 50% of global demand for various vaccines and 40% of generic demand in the US. The pharmaceutical sector was valued at US$ 33 billion in 2017 and is expected to grow at 15% annually. India accounts for 20% of global exports in generics. Exports stood at US$ 17.27 billion in FY18 and are projected to reach US$ 20 billion by 2020. The domestic market is expected to reach US$ 27.9 billion by 2020. Increased investment in R&D, acquisitions, and partnerships are driving growth in the Indian pharmaceutical sector.
Indian pharmaceutical industry is the third largest in terms of volume and is expected to grow to US$ 55 billion by 2020. It supplies over 50% of global demand for various vaccines and HIV/AIDS medicines. India accounts for 20% of global exports in generics. Exports stood at US$ 17.27 billion in FY18 and are expected to reach US$ 20 billion by 2020. The domestic market is expected to reach US$ 27.9 billion by 2020. India has a competitive advantage due to its low cost of production which is approximately 33% lower than the US. The government aims to make India a global leader in drug manufacturing through initiatives like 'Pharma Vision 2020'.
Indian pharmaceutical industry supplies over 50% of global demand for various vaccines and drugs. It is expected to grow at 22.4% annually to reach $55 billion by 2025. India accounts for 20% of global exports in generics. The domestic market is expected to reach $27.9 billion by 2020 with high potential for growth in generics. Increased investment in R&D and acquisitions are driving growth in the robust Indian pharmaceutical sector.
Indian pharmaceutical industry supplies over 50% of global demand for various vaccines and generic drugs. The pharmaceutical sector was valued at US$33 billion in 2017 and is expected to grow at 15% annually. India accounts for 20% of global exports in generics. Major export destinations include North America, Africa, and the European Union. Indian companies are increasing R&D spending to develop new drugs and looking for growth opportunities in global markets through exports and acquisitions.
The document provides an overview of the pharmaceutical industry in India. Some key points:
1. The Indian pharmaceutical industry is expected to grow to $100 billion by 2025 from $27.57 billion in 2016, expanding at a CAGR of 12.89% between 2015-2020.
2. India accounts for 20% of global exports in generics drugs, with exports standing at $16.84 billion in 2016-17 and projected to reach $20 billion by 2020.
3. The domestic generics drugs market was valued at $26.1 billion in 2016 and has significant potential for further growth.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- India supplies over 50% of global demand for various vaccines and generic drugs. The pharmaceutical sector was valued at $33 billion in 2017 and is expected to reach $55 billion by 2022, growing at 22.4% CAGR.
- India accounts for 20% of global exports in generics. Pharmaceutical exports were $17.27 billion in 2017-18 and are projected to reach $20 billion by 2020.
- The domestic generics market is expected to reach $27.9 billion by 2020 and has immense growth potential. Generic drugs account for 70% of the domestic market.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- India supplies over 50% of global demand for various vaccines and generic drugs. The pharmaceutical sector was valued at $33 billion in 2017 and is expected to reach $55 billion by 2022, growing at 22.4% CAGR.
- India accounts for 20% of global exports in generics. Pharmaceutical exports stood at $17.27 billion in 2017-18 and are expected to reach $20 billion by 2020.
- The domestic generics market is expected to reach $27.9 billion by 2020 and has immense growth potential. By 2024-25, the biotech industry is estimated to increase to $100 billion
Indian pharmaceutical industry is the third largest in terms of volume and provides over 50% of global demand for various vaccines, 40% of generic demand in US, and 25% of all medicine in UK. It is expected to grow at 22.4% annually to $55 billion by 2025. India accounts for 20% of global exports in generics with exports reaching $17.27 billion in 2017-18. The domestic market is expected to reach $27.9 billion by 2020 driven by increased healthcare spending and penetration of health insurance in India. The industry has immense potential for growth in generics, biotech and contract manufacturing segments.
Indian pharmaceutical industry supplies over 50% of global demand for various vaccines and 40% of generic demand in the US. The pharmaceutical sector was valued at US$ 33 billion in 2017 and is expected to grow at 15% annually. India accounts for 20% of global exports in generics. Exports stood at US$ 17.27 billion in FY18 and are projected to reach US$ 20 billion by 2020. The domestic market is expected to reach US$ 27.9 billion by 2020. Increased investment in R&D, acquisitions, and partnerships are driving growth in the Indian pharmaceutical sector.
Indian pharmaceutical industry is the third largest in terms of volume and is expected to grow to US$ 55 billion by 2020. It supplies over 50% of global demand for various vaccines and HIV/AIDS medicines. India accounts for 20% of global exports in generics. Exports stood at US$ 17.27 billion in FY18 and are expected to reach US$ 20 billion by 2020. The domestic market is expected to reach US$ 27.9 billion by 2020. India has a competitive advantage due to its low cost of production which is approximately 33% lower than the US. The government aims to make India a global leader in drug manufacturing through initiatives like 'Pharma Vision 2020'.
Indian pharmaceutical industry supplies over 50% of global demand for various vaccines and drugs. It is expected to grow at 22.4% annually to reach $55 billion by 2025. India accounts for 20% of global exports in generics. The domestic market is expected to reach $27.9 billion by 2020 with high potential for growth in generics. Increased investment in R&D and acquisitions are driving growth in the robust Indian pharmaceutical sector.
Indian pharmaceutical industry supplies over 50% of global demand for various vaccines and generic drugs. The pharmaceutical sector was valued at US$33 billion in 2017 and is expected to grow at 15% annually. India accounts for 20% of global exports in generics. Major export destinations include North America, Africa, and the European Union. Indian companies are increasing R&D spending to develop new drugs and looking for growth opportunities in global markets through exports and acquisitions.
The document provides an overview of the pharmaceutical industry in India. Some key points:
1. The Indian pharmaceutical industry is expected to grow to $100 billion by 2025 from $27.57 billion in 2016, expanding at a CAGR of 12.89% between 2015-2020.
2. India accounts for 20% of global exports in generics drugs, with exports standing at $16.84 billion in 2016-17 and projected to reach $20 billion by 2020.
3. The domestic generics drugs market was valued at $26.1 billion in 2016 and has significant potential for further growth.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- India supplies over 50% of global demand for various vaccines and generic drugs. The pharmaceutical sector was valued at $33 billion in 2017 and is expected to reach $55 billion by 2022, growing at 22.4% CAGR.
- India accounts for 20% of global exports in generics. Pharmaceutical exports were $17.27 billion in 2017-18 and are projected to reach $20 billion by 2020.
- The domestic generics market is expected to reach $27.9 billion by 2020 and has immense growth potential. Generic drugs account for 70% of the domestic market.
This is a very good presentation on Indian Pharmaceutical sector prepared by India Brand Equity Fund ( IBEF ) working under Commerce Ministry, Govt of India. A very good effort is made to cover all aspects of Indian pharma.They could have included ABLE also.
Industry CEOs can consider to use this ppt in overseas presentations.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- India is a major global player in pharmaceuticals, accounting for around 3% of the global industry. The market is expected to grow to $55 billion by 2020 and $100 billion by 2025.
- India has a large generics market and is a major exporter, accounting for 20% of global exports. Exports were $16.84 billion in 2016-17 and are projected to reach $20 billion by 2020.
- Key segments of the market include generics, Active Pharmaceutical Ingredients, Contract Research and Manufacturing Services, and biosimilars. Anti-infectives represent the largest segment dome
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical industry is expected to grow at a CAGR of 12.89% until 2020 to reach $55 billion in size.
- India accounts for 20% of global exports in generics drugs. Exports stood at $16.84 billion in 2016-17 and are expected to reach $20 billion by 2020.
- The domestic pharmaceutical market was worth $27.57 billion in 2016 and is estimated to have grown 7.4% to $29.61 billion in 2017. The market is expected to continue growing rapidly over the next few years.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical sector accounts for about 2.4% of the global pharmaceutical industry in value and is expected to grow at a CAGR of 12.89% to reach $55 billion by 2020.
- India accounts for 20% of global exports in generics drugs. Exports were $16.4 billion in 2016-17 and are expected to grow 30% to $20 billion by 2020.
- Generic drugs form the largest segment of the Indian pharmaceutical market, accounting for 70% of the market. Anti-infectives represent the largest therapeutic segment.
The document discusses India's advantages in low-
Indian pharmaceutical sector supplies over 50% of global demand for various vaccines and generic drugs. The market is expected to grow at a CAGR of 22.4% until 2020 to reach $55 billion. India accounts for 20% of global exports in generics. Key factors driving growth include rising income levels, increased healthcare access and greater penetration of health insurance. Indian companies are raising R&D spending and entering new markets to sustain growth in the face of increasing competition from global players.
Indian pharmaceutical sector is estimated to account for 3.1-3.6% of the global pharmaceutical industry in value terms and 10% in volume terms. The country's pharmaceutical industry is expected to expand at a CAGR of 12.89% over 2015-2020 to reach US$ 55 billion. India accounts for 20% of global exports in generics. By 2020, India is likely to be among the top three pharmaceutical markets by incremental growth and 6th largest market globally in absolute size. The generics market stood at US$ 26.1 billion in 2016 and has high potential for growth. By 2024-25, India's biotech industry is estimated to increase to US$ 100 billion from US$ 11 billion in F
India's oil and gas sector is dominated by state-owned companies. India is the third largest energy consumer globally and its energy demand is expected to double by 2035. Oil consumption has expanded at a CAGR of 4.78% during 2007-2017 to reach 4.69 million barrels per day in 2017, with India retaining its spot as the third largest oil consumer. Gas consumption has increased at a CAGR of 3.40% between 2007-2017 and demand is projected to further rise significantly by 2040. The country increasingly relies on imports to meet its growing demand for oil and gas.
The Indian pharmaceutical sector is estimated to reach $100 billion by 2025, accounting for 10% of the global pharmaceutical industry by volume. It currently accounts for 20% of global generic exports. The sector is expected to grow at a CAGR of 12.89% until 2020 to reach $55 billion. By 2020, India will be among the top 3 pharmaceutical markets by growth and 6th largest globally. The government has implemented policies and initiatives like 'PharmaVision 2020' to make India a global pharmaceutical leader and improve affordability and availability of medicines.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical industry is expected to grow to $55 billion by 2020, expanding at a CAGR of 12.89% from 2015-2020.
- India accounts for 20% of global exports in generics, with pharmaceutical exports at $16.84 billion in 2016-17, expected to reach $20 billion by 2020.
- The biotech industry in India is also growing rapidly, estimated to increase from $11 billion in 2015-16 to $100 billion by 2024-25.
The document provides an overview of the Indian pharmaceutical industry. It notes that the industry is expected to grow to $100 billion by 2025, making India one of the top global markets. Currently valued at $27.57 billion, the industry is growing at 12.89% annually and exports over $16 billion worth of drugs globally each year. The generics market and biotech sector also have strong growth potential. The industry benefits from low production costs, a large skilled workforce, and government support for further development.
This document discusses how the global healthcare profit pool will shift between 2010 and 2020. It predicts that the total profit pool will grow at 4% annually from $520 billion to $740 billion over this period. However, profitability will decline for most players as the sources of growth and margins change significantly between sectors and regions. Innovative pharmaceutical and medical technology companies will see much slower growth and declining margins. In contrast, providers of healthcare delivery and lower-margin sectors like generics will capture a larger share of profits. To remain competitive, companies will need to develop new business models focused on improving healthcare delivery and outcomes rather than just generating more products and procedures.
Indian pharmaceutical sector accounts for about 2.4% of the global pharmaceutical industry in value terms and 10% in volume terms. The country's pharmaceutical industry is expected to expand at a CAGR of 12.89% over 2015–20 to reach US$ 55 billion, making it among the fastest growing industries. India exports 20% of global exports in generics, with pharmaceutical exports at US$ 16.8 billion in 2016-17 and projected to reach US$ 20 billion by 2020. The generics market stood at US$ 26.1 billion in 2016 with high potential for growth. By 2024-25, India's biotech industry is estimated to increase to US$ 100 billion from US$ 11 billion in FY 2015
IMS - Global Use of Medicines 2020 by Nitesh BheleNitesh Bhele
By 2020, global medicine use will reach 4.5 trillion doses, a 24% increase from 2015 levels. Over half of the world's population will consume over 1 dose per person per day, driven by increased access in large emerging markets like India, China, Brazil, and Indonesia. Developed markets will continue to use more branded and specialty medicines per capita, while emerging markets will see greater use of generics and over-the-counter drugs. New medicines introduced in the past 10 years will account for 0.1% of volumes in emerging markets versus 2-3% in developed markets.
Indian Pharma market is predominantly a branded generic market. How does this auger for the industry per se, how is it then placed to grow going in the future. This brief presentation attempts to throw some light on the said topic
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical industry is expected to grow at a CAGR of 12.89% until 2020 to reach $55 billion in size.
- India accounts for 20% of global exports in generics drugs and exports were $16.8 billion in 2016-17, expected to reach $20 billion by 2020.
- The generics market in India stands at $26.1 billion in 2016 and has strong growth potential.
- Major segments of the pharmaceutical industry in India include active pharmaceutical ingredients, formulations, biosimilars, and contract research and manufacturing.
Indian Pharmaceutical Market Overview 2013 by Nitesh BheleNitesh Bhele
The document summarizes the Indian pharmaceutical market in 2013. It highlights that the Indian market was valued at around $10 billion and was expected to grow double digits in the next five years. The generic drugs market was estimated to make up around 90% of the prescription drug market by 2016. It also provides an overview of the key segments of the Indian pharmaceutical market, the largest global companies, top therapeutic classes and products, as well as government initiatives to support industry growth.
The document discusses the Indian pharmaceutical industry. It notes that India accounts for about 1.4% of the global pharma industry by value but 10% by volume. The industry is growing rapidly and is expected to reach $36 billion by 2016, expanding at a CAGR of 17.8%. India has a large and growing generics market, low-cost production, and government policy support promoting the pharmaceutical sector. The industry has significant export potential and is a major supplier of generic drugs globally.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- India supplies over 50% of global demand for various vaccines and 40% of generic drugs in the US. The pharmaceutical sector was valued at $33 billion in 2017.
- Exports have grown significantly, reaching $17.27 billion in FY2018. The domestic market is also growing rapidly and is expected to reach $27.9 billion by 2020.
- Growth is driven by low production costs, a large skilled workforce, increasing healthcare spending, and a large generics market. The government is also supporting industry growth through initiatives like increasing FDI limits.
This document provides an overview of the history and growth of the Indian pharmaceutical industry. It discusses how India's growing middle class and economy have increased healthcare spending and demand for drugs. It also summarizes how disease profiles are shifting towards more chronic conditions like diabetes. Government policies aim to improve healthcare access and spending. The pharmaceutical market and exports have grown significantly in recent decades and India has become a major supplier of generic drugs globally.
Advantages of Pharma in India, Market Share and Economic Drivers, Structure of Pharma Sector, Evolution of Pharma, Revenue %, Market Share, Porter 5 Force Model, BCG Matrix, Government Policies, Opportunities.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical industry is expected to grow at a CAGR of 12.89% until 2020 to reach $55 billion in size. India accounts for 20% of global generic drug exports.
- Major segments of the industry include active pharmaceutical ingredients, formulations, biosimilars, and contract research and manufacturing. Generics account for 70% of the domestic market.
- Leading therapeutic segments are anti-infectives, cardiovascular, and gastro-intestinal drugs. The biotechnology industry in India is also growing rapidly and is projected to reach $100 billion by 2025.
- Pharmaceutical exports from
Pharmaceutical marketing in the 21st centuryRamdas Dolas
The document discusses the pharmaceutical industry in India. It notes that India supplies over 50% of global demand for various vaccines, 40% of generic demand in the US, and 25% of medicine in the UK, making it a leading pharma producer. The industry is growing rapidly at a 22.4% CAGR and is valued at $33 billion in 2017. India also accounts for 20% of global exports in generics, with exports reaching $17.27 billion in 2017-18. The domestic generics market is large as well and expected to reach $27.9 billion by 2020. The biotech industry is also seeing robust growth and estimated to reach $100 billion by 2024-25.
This is a very good presentation on Indian Pharmaceutical sector prepared by India Brand Equity Fund ( IBEF ) working under Commerce Ministry, Govt of India. A very good effort is made to cover all aspects of Indian pharma.They could have included ABLE also.
Industry CEOs can consider to use this ppt in overseas presentations.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- India is a major global player in pharmaceuticals, accounting for around 3% of the global industry. The market is expected to grow to $55 billion by 2020 and $100 billion by 2025.
- India has a large generics market and is a major exporter, accounting for 20% of global exports. Exports were $16.84 billion in 2016-17 and are projected to reach $20 billion by 2020.
- Key segments of the market include generics, Active Pharmaceutical Ingredients, Contract Research and Manufacturing Services, and biosimilars. Anti-infectives represent the largest segment dome
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical industry is expected to grow at a CAGR of 12.89% until 2020 to reach $55 billion in size.
- India accounts for 20% of global exports in generics drugs. Exports stood at $16.84 billion in 2016-17 and are expected to reach $20 billion by 2020.
- The domestic pharmaceutical market was worth $27.57 billion in 2016 and is estimated to have grown 7.4% to $29.61 billion in 2017. The market is expected to continue growing rapidly over the next few years.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical sector accounts for about 2.4% of the global pharmaceutical industry in value and is expected to grow at a CAGR of 12.89% to reach $55 billion by 2020.
- India accounts for 20% of global exports in generics drugs. Exports were $16.4 billion in 2016-17 and are expected to grow 30% to $20 billion by 2020.
- Generic drugs form the largest segment of the Indian pharmaceutical market, accounting for 70% of the market. Anti-infectives represent the largest therapeutic segment.
The document discusses India's advantages in low-
Indian pharmaceutical sector supplies over 50% of global demand for various vaccines and generic drugs. The market is expected to grow at a CAGR of 22.4% until 2020 to reach $55 billion. India accounts for 20% of global exports in generics. Key factors driving growth include rising income levels, increased healthcare access and greater penetration of health insurance. Indian companies are raising R&D spending and entering new markets to sustain growth in the face of increasing competition from global players.
Indian pharmaceutical sector is estimated to account for 3.1-3.6% of the global pharmaceutical industry in value terms and 10% in volume terms. The country's pharmaceutical industry is expected to expand at a CAGR of 12.89% over 2015-2020 to reach US$ 55 billion. India accounts for 20% of global exports in generics. By 2020, India is likely to be among the top three pharmaceutical markets by incremental growth and 6th largest market globally in absolute size. The generics market stood at US$ 26.1 billion in 2016 and has high potential for growth. By 2024-25, India's biotech industry is estimated to increase to US$ 100 billion from US$ 11 billion in F
India's oil and gas sector is dominated by state-owned companies. India is the third largest energy consumer globally and its energy demand is expected to double by 2035. Oil consumption has expanded at a CAGR of 4.78% during 2007-2017 to reach 4.69 million barrels per day in 2017, with India retaining its spot as the third largest oil consumer. Gas consumption has increased at a CAGR of 3.40% between 2007-2017 and demand is projected to further rise significantly by 2040. The country increasingly relies on imports to meet its growing demand for oil and gas.
The Indian pharmaceutical sector is estimated to reach $100 billion by 2025, accounting for 10% of the global pharmaceutical industry by volume. It currently accounts for 20% of global generic exports. The sector is expected to grow at a CAGR of 12.89% until 2020 to reach $55 billion. By 2020, India will be among the top 3 pharmaceutical markets by growth and 6th largest globally. The government has implemented policies and initiatives like 'PharmaVision 2020' to make India a global pharmaceutical leader and improve affordability and availability of medicines.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical industry is expected to grow to $55 billion by 2020, expanding at a CAGR of 12.89% from 2015-2020.
- India accounts for 20% of global exports in generics, with pharmaceutical exports at $16.84 billion in 2016-17, expected to reach $20 billion by 2020.
- The biotech industry in India is also growing rapidly, estimated to increase from $11 billion in 2015-16 to $100 billion by 2024-25.
The document provides an overview of the Indian pharmaceutical industry. It notes that the industry is expected to grow to $100 billion by 2025, making India one of the top global markets. Currently valued at $27.57 billion, the industry is growing at 12.89% annually and exports over $16 billion worth of drugs globally each year. The generics market and biotech sector also have strong growth potential. The industry benefits from low production costs, a large skilled workforce, and government support for further development.
This document discusses how the global healthcare profit pool will shift between 2010 and 2020. It predicts that the total profit pool will grow at 4% annually from $520 billion to $740 billion over this period. However, profitability will decline for most players as the sources of growth and margins change significantly between sectors and regions. Innovative pharmaceutical and medical technology companies will see much slower growth and declining margins. In contrast, providers of healthcare delivery and lower-margin sectors like generics will capture a larger share of profits. To remain competitive, companies will need to develop new business models focused on improving healthcare delivery and outcomes rather than just generating more products and procedures.
Indian pharmaceutical sector accounts for about 2.4% of the global pharmaceutical industry in value terms and 10% in volume terms. The country's pharmaceutical industry is expected to expand at a CAGR of 12.89% over 2015–20 to reach US$ 55 billion, making it among the fastest growing industries. India exports 20% of global exports in generics, with pharmaceutical exports at US$ 16.8 billion in 2016-17 and projected to reach US$ 20 billion by 2020. The generics market stood at US$ 26.1 billion in 2016 with high potential for growth. By 2024-25, India's biotech industry is estimated to increase to US$ 100 billion from US$ 11 billion in FY 2015
IMS - Global Use of Medicines 2020 by Nitesh BheleNitesh Bhele
By 2020, global medicine use will reach 4.5 trillion doses, a 24% increase from 2015 levels. Over half of the world's population will consume over 1 dose per person per day, driven by increased access in large emerging markets like India, China, Brazil, and Indonesia. Developed markets will continue to use more branded and specialty medicines per capita, while emerging markets will see greater use of generics and over-the-counter drugs. New medicines introduced in the past 10 years will account for 0.1% of volumes in emerging markets versus 2-3% in developed markets.
Indian Pharma market is predominantly a branded generic market. How does this auger for the industry per se, how is it then placed to grow going in the future. This brief presentation attempts to throw some light on the said topic
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical industry is expected to grow at a CAGR of 12.89% until 2020 to reach $55 billion in size.
- India accounts for 20% of global exports in generics drugs and exports were $16.8 billion in 2016-17, expected to reach $20 billion by 2020.
- The generics market in India stands at $26.1 billion in 2016 and has strong growth potential.
- Major segments of the pharmaceutical industry in India include active pharmaceutical ingredients, formulations, biosimilars, and contract research and manufacturing.
Indian Pharmaceutical Market Overview 2013 by Nitesh BheleNitesh Bhele
The document summarizes the Indian pharmaceutical market in 2013. It highlights that the Indian market was valued at around $10 billion and was expected to grow double digits in the next five years. The generic drugs market was estimated to make up around 90% of the prescription drug market by 2016. It also provides an overview of the key segments of the Indian pharmaceutical market, the largest global companies, top therapeutic classes and products, as well as government initiatives to support industry growth.
The document discusses the Indian pharmaceutical industry. It notes that India accounts for about 1.4% of the global pharma industry by value but 10% by volume. The industry is growing rapidly and is expected to reach $36 billion by 2016, expanding at a CAGR of 17.8%. India has a large and growing generics market, low-cost production, and government policy support promoting the pharmaceutical sector. The industry has significant export potential and is a major supplier of generic drugs globally.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- India supplies over 50% of global demand for various vaccines and 40% of generic drugs in the US. The pharmaceutical sector was valued at $33 billion in 2017.
- Exports have grown significantly, reaching $17.27 billion in FY2018. The domestic market is also growing rapidly and is expected to reach $27.9 billion by 2020.
- Growth is driven by low production costs, a large skilled workforce, increasing healthcare spending, and a large generics market. The government is also supporting industry growth through initiatives like increasing FDI limits.
This document provides an overview of the history and growth of the Indian pharmaceutical industry. It discusses how India's growing middle class and economy have increased healthcare spending and demand for drugs. It also summarizes how disease profiles are shifting towards more chronic conditions like diabetes. Government policies aim to improve healthcare access and spending. The pharmaceutical market and exports have grown significantly in recent decades and India has become a major supplier of generic drugs globally.
Advantages of Pharma in India, Market Share and Economic Drivers, Structure of Pharma Sector, Evolution of Pharma, Revenue %, Market Share, Porter 5 Force Model, BCG Matrix, Government Policies, Opportunities.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical industry is expected to grow at a CAGR of 12.89% until 2020 to reach $55 billion in size. India accounts for 20% of global generic drug exports.
- Major segments of the industry include active pharmaceutical ingredients, formulations, biosimilars, and contract research and manufacturing. Generics account for 70% of the domestic market.
- Leading therapeutic segments are anti-infectives, cardiovascular, and gastro-intestinal drugs. The biotechnology industry in India is also growing rapidly and is projected to reach $100 billion by 2025.
- Pharmaceutical exports from
Pharmaceutical marketing in the 21st centuryRamdas Dolas
The document discusses the pharmaceutical industry in India. It notes that India supplies over 50% of global demand for various vaccines, 40% of generic demand in the US, and 25% of medicine in the UK, making it a leading pharma producer. The industry is growing rapidly at a 22.4% CAGR and is valued at $33 billion in 2017. India also accounts for 20% of global exports in generics, with exports reaching $17.27 billion in 2017-18. The domestic generics market is large as well and expected to reach $27.9 billion by 2020. The biotech industry is also seeing robust growth and estimated to reach $100 billion by 2024-25.
- India is a leading producer of pharmaceuticals, accounting for around 2.4% of global pharma production by value and 10% by volume. It exports $16.89 billion worth of drugs annually.
- The Indian pharma market was worth $36.7 billion in 2016 and is expected to reach $55 billion by 2020, growing at a CAGR of 12.89%. Generics account for 70% of the domestic market.
- India has a large, diverse pharma industry with over 60,000 generic brands across 60 therapeutic categories. Production costs are much lower than in Western markets, boosting Indian competitiveness.
The document provides information on trends in the Indian pharmaceutical sector. It notes that Indian pharmaceutical companies are increasing spending on research and development to develop new drugs. Exports of pharmaceutical products from India have grown significantly in recent years and are expected to exceed USD15 billion in 2015, as Indian companies have a strong presence in the generics market. The top four pharmaceutical firms in India by revenue - Dr. Reddy's, Lupin, Cipla and Aurobindo - account for over 20% of the domestic market share. Anti-infective drugs represent the largest segment of the Indian pharmaceutical market. Exports and domestic sales have increased the size of the Indian pharmaceutical market to USD36.7 billion in 2016.
The document provides an overview of the pharmaceutical sector in India. It discusses key trends in the Indian pharmaceutical market including growing demand, cost advantages, policy support, and a diversified product portfolio. It also outlines the structure and evolution of the pharmaceutical industry in India. The generics market is the largest segment and anti-infectives lead in terms of market share. Exports are a major focus and have grown significantly in recent years. The top firms invest heavily in R&D and account for over 20% of the domestic market.
The document provides information on the pharmaceutical industry in India. Some key points:
- India accounts for 20% of global pharmaceutical exports and the domestic market is expected to reach $55 billion by 2020, growing at a CAGR of 12.89% from 2015-2020.
- The generics market is the largest segment in India, accounting for 70% of the domestic market. India supplies 20% of global generic medicines by volume.
- Key growth drivers for the industry include low production costs, growing demand, policy support from the government, and a large/diversified product portfolio. The industry attracted 5% of total FDI into India from 2000-2016.
The document provides an overview of the Indian pharmaceutical industry, including its history, growth, market structure, competition, exports and imports, and the effects of foreign investment. Some key points:
- The industry has grown significantly since its early years and now accounts for 8% of global pharmaceutical production.
- Major players include Ranbaxy, Dr. Reddy's Laboratories, Sun Pharmaceuticals, and AurobindoPharma.
- Exports have shown strong growth and now contribute around half of revenue for top companies. The US and Europe are major export markets.
- Foreign investment has impacted areas like new drug development, manufacturing standards, and marketing skills. Mauritius is a significant source of foreign
The document provides an overview of key trends in the Indian pharmaceutical sector:
- Indian pharmaceutical companies are increasing spending on research and development between 8-11% of total turnover to develop new drugs and boost sales.
- Pharmaceutical exports from India are thriving, particularly in generics, with exports exceeding $15 billion in 2015 and reaching $16.89 billion in 2016.
- Multinational companies are collaborating with Indian firms through joint ventures to develop new drugs, while Indian players are also expanding operations abroad.
The document provides an overview of the pharmaceutical sector in India. Some key points:
- India is a leading global producer of generic drugs and vaccines, accounting for 20% of global exports. The domestic market was worth $36.7 billion in 2016 and is forecast to reach $55 billion by 2020.
- The sector benefits from low production costs which are 60% lower than the US and half of Europe. Government policies also support the growth of the sector.
- Generics account for 70% of the domestic market, while chronic therapies like cardiovascular, anti-diabetic, and anti-infectives are major segments. Exports and domestic demand are driving continued expansion of the industry.
1) By 2020, the Indian pharmaceutical industry is projected to grow to $50 billion and become one of the top 10 pharmaceutical markets globally, driven by strong domestic demand and increased exports.
2) Generics are expected to continue dominating the market, accounting for around 90% of the pharmaceutical formulation market. Patent-protected drugs will make up about 10% of the market.
3) Increased healthcare infrastructure investment, rising incomes, health insurance expansion, and government programs are expected to drive growth in domestic pharmaceutical demand and help increase accessibility of drugs across India. Chronic diseases will account for over half of the pharmaceutical market.
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...Irish Pereira
By Mr. Irish Pereira. The report present snapshot of Indian Pharmaceutical industry in both domestic as well as export market. It is collation of facts pertaining to Indian pharma exports and explore key emerging trends pertaining to pharma export market. It describes key players of Indian pharma market and their export orientation as in their target export destinations, their focus therapies etc.
Fact sheet:
1) Indian Pharma Market size 2015
2) Indian pharmaceutical market segments by value
3)Patented (Innovator) Vs Generics Scenario
4)Growth drivers of Indian pharmaceutical industry
5) Indian Pharmaceutical sector – SWOT Analysis
6)PHARMEXCIL – Facilitating agency for Indian Pharma Exports
7) Indian Pharmaceutical Exports (USD bn)
8)Formulations share in Total Pharma Exports (2014-15)
9) Top 25 destination countries of India’s pharmaceutical exports during 2013-14 (INR mn)
10) Major Indian Pharma Companies (By Revenue-USD mn)
11) Pharma players and their export destinations
Sun Pharma,Dr. Reddy’s Lab,
CIPLA, Lupin, Aurobindo, Cadila Healthcare, Torrent Pharma, Wockhardt,
12) Emerging trends in Indian Pharma Market
India is the largest producer of Generic drugs globally and a major supplier of vaccines. For India, this industry earns significant trade surplus and FDI. Let us talk about this industry.
Introduction to indian pharma industriespharmacampus
Introduction to Indian Pharma Industries: this highlights leading pharma producers, details of exports of medicines, growth statistics, and high potential generic market.
The document provides information on the pharmaceutical sector in India. Some key points:
- India accounts for approximately 10% of global pharmaceutical production and is the largest provider of generic medicines globally. Exports of pharmaceutical products from India reached USD 16.89 billion in FY2016.
- The domestic pharmaceutical market was worth USD 27.57 billion in 2016 and is expected to reach USD 55 billion by 2020, growing at a CAGR of 12.89% from 2015-2020. Generics account for 70% of the domestic market.
- Leading players like Dr. Reddy's, Lupin, Cipla and Aurobindo account for over 20% of the domestic market. Top companies are
The document provides information on trends in the Indian pharmaceutical sector:
- R&D spending by major Indian pharmaceutical companies is increasing, with Sun Pharma spending the most at $352 million in FY16. Lupin expects R&D spending to be 12-15% of sales in FY17.
- Exports of pharmaceutical products from India have been rapidly growing and exceeded $16.89 billion in FY16, expected to reach $40 billion by 2020. Generic drugs account for 20% of global exports by volume.
- The top four pharmaceutical companies in India - Dr. Reddy's, Lupin, Cipla, and Aurobindo - captured over 20% of the
The document provides an overview of the pharmaceutical sector in India. Some key points:
- India accounts for 10% of global pharmaceutical production and 20% of global generics exports. Exports grew 9.44% in FY2016 to $16.89 billion.
- The domestic market was worth $27.57 billion in 2016 and is projected to reach $55 billion by 2020, growing at a CAGR of 12.89%. Generics account for 70% of the market.
- Major players include Dr. Reddy's, Lupin, Cipla and Aurobindo, who collectively account for over 20% of the market. Companies are increasing R&D spending to develop new drugs
The document provides an overview of the pharmaceutical industry in India. Some key points:
- India is a major global supplier of generic drugs, accounting for 20% of global exports. The pharmaceutical industry is expected to grow to $55 billion by 2020 from $27.57 billion in 2016.
- The industry benefits from low production costs, which are 60% lower than the US and half of Europe. Government policies also support the industry through initiatives like 'Pharma Vision 2020'.
- Generics account for 70% of the domestic pharmaceutical market. The largest segments by therapy are anti-infectives at 16%, cardiovascular at 13%, and gastrointestinal at 11%.
NEW ERA OF DRUG PRODUCT: OPPORTUNITIES AND CHALLENGESganpat420
Abstract
Introduction
Global pharmaceutical industry
Indian pharmaceutical industry
Indian Pharmaceutical Market
Opportunities
Challenges
Conclusion
References
Similar to Pharmaceuticals Sector Report - September 2018 (18)
Tamil Nadu has a strong and growing economy, as evidenced by its GSDP which grew at a CAGR of 11.46% between 2011-12 and 2018-19, reaching Rs. 16.06 trillion (US$ 222.58 billion) in 2018-19. The state has a diversified industrial base and thriving services sector, especially in IT/ITeS. It also has robust infrastructure including roads, ports, airports, and an emphasis on further infrastructure development. With various initiatives like Vision 2023, Tamil Nadu aims to boost its economy and attract significant domestic and foreign investments over the coming years.
India has become the second largest steel producer in the world in 2018. Steel production and capacity in India have grown rapidly over the past decade, with capacity reaching 137.98 million tonnes in 2017-18. Consumption has also increased steadily, driven by growth in infrastructure, automotive, and other sectors. The government has implemented policies like the National Steel Policy to encourage further capacity growth to 300 million tonnes by 2030-31. Low per capita consumption compared to other countries also provides significant potential for further demand growth.
The document provides an overview of India's services sector, including:
1) The services sector contributes over 50% of India's GDP and grew at 12.75% in 2018-19, demonstrating its importance as the key driver of India's economic growth.
2) India has a large skilled workforce and is a global outsourcing hub, commanding a 55% share of the global sourcing market, which has helped establish the country as a leading provider of technology and digital services.
3) The government is working to further develop the services sector through initiatives like 'Startup India' and reforms that make India an attractive investment destination for both domestic and foreign investors.
The document provides an overview of the real estate sector in India. It discusses that the real estate sector is expected to reach $1 trillion by 2030 and contribute 13% of India's GDP by 2025. Rapid urbanization is driving demand for residential and commercial real estate space. The residential segment contributes around 80% of the sector currently. Government policies like Housing for All and Smart Cities are further boosting growth.
Rajasthan has experienced strong economic growth in recent years. Between 2011-12 and 2018-19, the state's Gross State Domestic Product grew at a compound annual growth rate of 11.37% to reach $128.1 billion. The tourism industry in Rajasthan is thriving, with over 47.5 million tourist arrivals in 2017, and the state is a leading producer of agro-based products. Rajasthan also has immense potential for renewable energy generation from solar and wind sources.
Indian Railways is the third largest rail network in the world by size. It saw strong revenue growth over the past decade, with freight accounting for over 65% of revenues in FY19. Freight and passenger traffic have both increased steadily in recent years. Various modernization initiatives are underway to upgrade infrastructure and technology. Private sector participation is being encouraged to augment rail connectivity and capacity.
India has the third largest installed power capacity in the world at 356.10 GW as of March 2019. It is the third largest producer and consumer of electricity globally. India has achieved 100% household electrification and aims to increase renewable energy capacity to 175 GW by 2022. Thermal energy accounts for over 63% of total installed capacity, while renewable sources account for 21.8%. The power sector in India is growing rapidly and offers many opportunities for investment and development.
Nagaland has a Gross State Domestic Product (GSDP) of around 0.24 trillion Indian rupees in 2017-18, growing at a CAGR of 11.83% between 2011-12 and 2017-19. The per capita GSDP in 2017-18 was 113,549 rupees, growing at a CAGR of 10.66% in the same period. Nagaland's Net State Domestic Product (NSDP) in 2016-17 was 0.19 trillion rupees, growing at 15.72% between 2011-12 and 2016-17. The per capita NSDP in 2016-17 was 90,168 rupees, growing at 12.
Meghalaya has the highest rainfall in India and diverse soil types that support agriculture. The state has strong potential in floriculture, bamboo processing, and medicinal plants due to its biodiversity. Meghalaya also has large hydroelectric power potential and abundant mineral resources. The state aims to promote industries like agro-processing, horticulture, minerals and tourism to create opportunities for its population.
- The Indian infrastructure sector is experiencing significant growth due to rising government investments and initiatives such as allocating Rs 4.56 lakh crore for infrastructure in the FY 2019-20 budget.
- Private sector participation is increasing across segments like roads, power and airports. Infrastructure sectors like power transmission and renewable energy will drive future investments.
- Improving connectivity through initiatives like Bharatmala Pariyojana and Sagarmala will boost infrastructure growth. 100% villages connectivity through roads is expected by 2019 under PMGSY.
The document provides an overview of the media and entertainment industry in India. Some of the key points from the document are:
- The Indian media and entertainment industry is growing rapidly at a CAGR of 12-13% and is expected to reach Rs. 3.73 lakh crore by 2022.
- Television is the largest segment with a market size of Rs. 740 billion in 2018, expected to reach Rs. 955 billion by 2021. Digital media, animation and VFX, and online gaming are among the fastest growing segments.
- Advantages for the industry in India include rising incomes, evolving lifestyles, a large young population, increasing digitization, and government support through
- The manufacturing sector is a major employer in India and aims to provide 25% of GDP and 100 million new jobs by 2022. It has grown at a CAGR of 4% between FY12-19 and contributes significantly to India's exports.
- The document discusses India's advantage in manufacturing including a large domestic market, favorable demographics, and government initiatives like Make in India. Key sub-sectors, growth drivers and the evolution of the sector are also outlined.
- Recent trends show growth in production, IIP, capacity utilization and exports, indicating the sector is expanding. The government has implemented various policies to develop manufacturing and make India a global hub.
Manipur has a flourishing bamboo processing industry as it is one of India's largest bamboo producing states. It also has a strong handicrafts industry, being home to the highest number of handicraft units and artisans in North East India. Handlooms is the largest cottage industry in Manipur. The state has strong potential for border trade opportunities through Moreh town, which is India's only land route for trade with Myanmar and Southeast Asia. Manipur is also home to the Ema Bazaar, one of India's largest markets run exclusively by women. Due to its natural beauty and biodiversity, Manipur is a popular tourist destination known as the "Switzerland of the East".
The document provides an overview of the economy of Himachal Pradesh, India. Some key points:
- Himachal Pradesh has a strong economic growth rate, with its GSDP reaching Rs. 1.52 trillion (US$21.04 billion) in 2018-19 growing at 11.09% annually.
- The state has a diverse economy with key sectors being tourism, agriculture, and hydroelectric power. Agricultural production and tourism visitor numbers are increasing.
- Himachal Pradesh has a large hydroelectric power potential and is becoming a major hub for hydroelectricity in India, though only around 40% of its potential has been harnessed so far.
Gujarat has experienced high economic growth rates in recent years.
- Gujarat's GSDP grew at a CAGR of 13.55% from 2011-12 to 2016-17, reaching Rs. 11.62 trillion (US$ 173.24 billion) in 2016-17.
- The state's per capita GSDP increased from Rs. 101,075 (US$ 2,108) in 2011-12 to Rs. 178,043 (US$ 2,654) in 2016-17, registering a CAGR of 11.99%.
The document provides an overview of India's gems and jewellery sector. Some key points:
- India is a major player in global gems and jewellery trade, contributing about 7% to India's GDP and employing over 4.6 million people.
- India is the world's largest cut and polished diamond exporter, exporting over 75% of global polished diamonds. It also processes over $23 billion worth of diamonds annually.
- Exports of cut and polished diamonds and gold jewellery have registered steady growth in recent years. Imports have also increased at a CAGR of nearly 8% between 2004-2018.
- The sector is adopting strategies like expanding retail networks, providing financing options
The engineering and capital goods industry in India is growing rapidly. The turnover of the capital goods industry reached $70 billion in 2017 and is forecasted to reach $115.17 billion by 2025. Electrical equipment production is also growing and is expected to reach $100 billion by 2022, up from $27.3 billion in 2017-18. The engineering research and design segment is also expanding, with revenues projected to increase from $28 billion in FY18 to $42 billion in FY22. Growth is being driven by increasing industrialization, infrastructure development, and capacity expansion across various core sectors in India.
Major e-commerce players in India have adopted strategies like expanding into new categories like groceries and used goods, acquiring analytics startups to improve pricing and positioning, and launching ancillary services like payments, logistics and video streaming. They have also introduced subscription models and personalized experiences to provide extra benefits and tailor their offerings to individual customer needs and interests.
Delhi has experienced strong economic growth, with its gross state domestic product increasing at a compound annual growth rate of 12.41% between 2011-12 and 2018-19. The real estate sector has been an important contributor to the state's economy. Delhi also has a growing tourism industry, owing to its historical and cultural attractions. The state government is working to improve infrastructure and implement policies to facilitate industrial development and attract investment across various sectors.
Chhattisgarh has a strong mineral production base and is a leading producer of coal and iron ore in India. It is the only state that produces tin concentrates. The state has emerged as a preferred investment destination and has witnessed strong growth in the agriculture sector. Key sectors driving growth include minerals, power, agriculture and tourism. Chhattisgarh aims to further develop its infrastructure, promote industries and boost skill development to achieve its vision of becoming an industrialized state.
^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Duba...mayaclinic18
Whatsapp (+971581248768) Buy Abortion Pills In Dubai/ Qatar/Kuwait/Doha/Abu Dhabi/Alain/RAK City/Satwa/Al Ain/Abortion Pills For Sale In Qatar, Doha. Abu az Zuluf. Abu Thaylah. Ad Dawhah al Jadidah. Al Arish, Al Bida ash Sharqiyah, Al Ghanim, Al Ghuwariyah, Qatari, Abu Dhabi, Dubai.. WHATSAPP +971)581248768 Abortion Pills / Cytotec Tablets Available in Dubai, Sharjah, Abudhabi, Ajman, Alain, Fujeira, Ras Al Khaima, Umm Al Quwain., UAE, buy cytotec in Dubai– Where I can buy abortion pills in Dubai,+971582071918where I can buy abortion pills in Abudhabi +971)581248768 , where I can buy abortion pills in Sharjah,+97158207191 8where I can buy abortion pills in Ajman, +971)581248768 where I can buy abortion pills in Umm al Quwain +971)581248768 , where I can buy abortion pills in Fujairah +971)581248768 , where I can buy abortion pills in Ras al Khaimah +971)581248768 , where I can buy abortion pills in Alain+971)581248768 , where I can buy abortion pills in UAE +971)581248768 we are providing cytotec 200mg abortion pill in dubai, uae.Medication abortion offers an alternative to Surgical Abortion for women in the early weeks of pregnancy. Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman
In a tight labour market, job-seekers gain bargaining power and leverage it into greater job quality—at least, that’s the conventional wisdom.
Michael, LMIC Economist, presented findings that reveal a weakened relationship between labour market tightness and job quality indicators following the pandemic. Labour market tightness coincided with growth in real wages for only a portion of workers: those in low-wage jobs requiring little education. Several factors—including labour market composition, worker and employer behaviour, and labour market practices—have contributed to the absence of worker benefits. These will be investigated further in future work.
Discover the Future of Dogecoin with Our Comprehensive Guidance36 Crypto
Learn in-depth about Dogecoin's trajectory and stay informed with 36crypto's essential and up-to-date information about the crypto space.
Our presentation delves into Dogecoin's potential future, exploring whether it's destined to skyrocket to the moon or face a downward spiral. In addition, it highlights invaluable insights. Don't miss out on this opportunity to enhance your crypto understanding!
https://36crypto.com/the-future-of-dogecoin-how-high-can-this-cryptocurrency-reach/
A toxic combination of 15 years of low growth, and four decades of high inequality, has left Britain poorer and falling behind its peers. Productivity growth is weak and public investment is low, while wages today are no higher than they were before the financial crisis. Britain needs a new economic strategy to lift itself out of stagnation.
Scotland is in many ways a microcosm of this challenge. It has become a hub for creative industries, is home to several world-class universities and a thriving community of businesses – strengths that need to be harness and leveraged. But it also has high levels of deprivation, with homelessness reaching a record high and nearly half a million people living in very deep poverty last year. Scotland won’t be truly thriving unless it finds ways to ensure that all its inhabitants benefit from growth and investment. This is the central challenge facing policy makers both in Holyrood and Westminster.
What should a new national economic strategy for Scotland include? What would the pursuit of stronger economic growth mean for local, national and UK-wide policy makers? How will economic change affect the jobs we do, the places we live and the businesses we work for? And what are the prospects for cities like Glasgow, and nations like Scotland, in rising to these challenges?
Vicinity Jobs’ data includes more than three million 2023 OJPs and thousands of skills. Most skills appear in less than 0.02% of job postings, so most postings rely on a small subset of commonly used terms, like teamwork.
Laura Adkins-Hackett, Economist, LMIC, and Sukriti Trehan, Data Scientist, LMIC, presented their research exploring trends in the skills listed in OJPs to develop a deeper understanding of in-demand skills. This research project uses pointwise mutual information and other methods to extract more information about common skills from the relationships between skills, occupations and regions.
Falcon stands out as a top-tier P2P Invoice Discounting platform in India, bridging esteemed blue-chip companies and eager investors. Our goal is to transform the investment landscape in India by establishing a comprehensive destination for borrowers and investors with diverse profiles and needs, all while minimizing risk. What sets Falcon apart is the elimination of intermediaries such as commercial banks and depository institutions, allowing investors to enjoy higher yields.
OJP data from firms like Vicinity Jobs have emerged as a complement to traditional sources of labour demand data, such as the Job Vacancy and Wages Survey (JVWS). Ibrahim Abuallail, PhD Candidate, University of Ottawa, presented research relating to bias in OJPs and a proposed approach to effectively adjust OJP data to complement existing official data (such as from the JVWS) and improve the measurement of labour demand.
Enhancing Asset Quality: Strategies for Financial Institutionsshruti1menon2
Ensuring robust asset quality is not just a mere aspect but a critical cornerstone for the stability and success of financial institutions worldwide. It serves as the bedrock upon which profitability is built and investor confidence is sustained. Therefore, in this presentation, we delve into a comprehensive exploration of strategies that can aid financial institutions in achieving and maintaining superior asset quality.
South Dakota State University degree offer diploma Transcriptynfqplhm
办理美国SDSU毕业证书制作南达科他州立大学假文凭定制Q微168899991做SDSU留信网教留服认证海牙认证改SDSU成绩单GPA做SDSU假学位证假文凭高仿毕业证GRE代考如何申请南达科他州立大学South Dakota State University degree offer diploma Transcript
Fabular Frames and the Four Ratio ProblemMajid Iqbal
Digital, interactive art showing the struggle of a society in providing for its present population while also saving planetary resources for future generations. Spread across several frames, the art is actually the rendering of real and speculative data. The stereographic projections change shape in response to prompts and provocations. Visitors interact with the model through speculative statements about how to increase savings across communities, regions, ecosystems and environments. Their fabulations combined with random noise, i.e. factors beyond control, have a dramatic effect on the societal transition. Things get better. Things get worse. The aim is to give visitors a new grasp and feel of the ongoing struggles in democracies around the world.
Stunning art in the small multiples format brings out the spatiotemporal nature of societal transitions, against backdrop issues such as energy, housing, waste, farmland and forest. In each frame we see hopeful and frightful interplays between spending and saving. Problems emerge when one of the two parts of the existential anaglyph rapidly shrinks like Arctic ice, as factors cross thresholds. Ecological wealth and intergenerational equity areFour at stake. Not enough spending could mean economic stress, social unrest and political conflict. Not enough saving and there will be climate breakdown and ‘bankruptcy’. So where does speculative design start and the gambling and betting end? Behind each fabular frame is a four ratio problem. Each ratio reflects the level of sacrifice and self-restraint a society is willing to accept, against promises of prosperity and freedom. Some values seem to stabilise a frame while others cause collapse. Get the ratios right and we can have it all. Get them wrong and things get more desperate.
Abhay Bhutada, the Managing Director of Poonawalla Fincorp Limited, is an accomplished leader with over 15 years of experience in commercial and retail lending. A Qualified Chartered Accountant, he has been pivotal in leveraging technology to enhance financial services. Starting his career at Bank of India, he later founded TAB Capital Limited and co-founded Poonawalla Finance Private Limited, emphasizing digital lending. Under his leadership, Poonawalla Fincorp achieved a 'AAA' credit rating, integrating acquisitions and emphasizing corporate governance. Actively involved in industry forums and CSR initiatives, Abhay has been recognized with awards like "Young Entrepreneur of India 2017" and "40 under 40 Most Influential Leader for 2020-21." Personally, he values mindfulness, enjoys gardening, yoga, and sees every day as an opportunity for growth and improvement.
Falcon stands out as a top-tier P2P Invoice Discounting platform in India, bridging esteemed blue-chip companies and eager investors. Our goal is to transform the investment landscape in India by establishing a comprehensive destination for borrowers and investors with diverse profiles and needs, all while minimizing risk. What sets Falcon apart is the elimination of intermediaries such as commercial banks and depository institutions, allowing investors to enjoy higher yields.
2. Table of Content
Executive Summary……………….….…….3
Advantage India…………………..….…......4
Market Overview …………….……….…….6
Recent trends and Strategies……...…..…14
Growth Drivers……………………..............18
Opportunities…….……….......………….…28
Useful Information……….......………….….30
3. For updated information, please visit www.ibef.orgPharmaceuticals3
EXECUTIVE SUMMARY
Source: 1 FICCI - Trends & Opportunities for Indian Pharma 2018, Pharmexcil, 2TechSci Research, Assocham and RNCOS
Notes: Information as per latest available data
Indian pharmaceutical industry supplies over 50 per cent of global demand for various vaccines, 40 per cent
of generic demand in the US and 25 per cent of all medicine in UK1.
Leading pharma
producer
The country’s pharmaceutical industry is expected to expand at a CAGR of 22.4 per cent over 2015–20 to
reach US$ 55 billion2. India is the second largest contributor of global biotech and pharmaceutical workforce.
The pharmaceutical sector was valued at US$ 33 billion in 2017.
Among fastest growing
industries
India accounts for 20 per cent of global exports in generics. India’s pharmaceutical exports stood at US$
17.27 billion in 2017-18 and are expected to reach US$ 20 billion by 2020. In 2018-19 these exports are
expected to cross US$ 19 billion.
One of the highest
exports
Indian healthcare sector, one of the fastest growing sectors, is expected to cross US$ 372 billion by 2022.
Rapidly growing
healthcare sector
The domestic generics market is expected to reach US$ 27.9 billion by 2020. India’s generics market has
immense potential for growth. Indian pharmaceutical companies received record 300 generic drug approvals
in USA during 2017 where the generic market is expected to reach US$ 88 billion by 2021.
High potential generics
market
By 2024-25, India’s biotech industry is estimated to increase to US$ 100 billion.
Robust growth in Biotech
industry
5. For updated information, please visit www.ibef.orgPharmaceuticals5
ADVANTAGE INDIA
Low cost of production and R&D boosts efficiency of
Indian pharma companies.
India’s cost of production is approximately 33 per cent
lower than that of the US.
Due to lower cost of treatment, India is emerging as a
leading destination for medical tourism.
India’s ability to
manufacture high quality, low priced
medicines, presents a huge business
opportunity for the domestic industry.
Economic prosperity to improve drug
affordability
Increasing penetration of health
insurance
With increasing penetration of
pharmacies, especially in rural India,
OTC drugs will be readily available
Accounts for over 10 per cent of the
global pharmaceutical production.
Over 60,000 generic brands across 60
therapeutic categories. Manufactures
more than 500 different APIs.
Government unveiled ‘Pharma
Vision 2020’ aimed at making India a
global leader in end-to-end drug
manufacturing.
Reduced approval time for new
facilities to boost investments.
In this sector, 100 per cent FDI is
allowed under automatic route.
ADVANTAGE
INDIA
Source: PwC, McKinsey, Pharmaceuticals Exports Promotion Council of India
Note: 2020 revenue forecasts are estimates of McKinsey, API - Active Pharmaceutical Ingredients, F – Forecast, OTC - Over-The-Counter
7. For updated information, please visit www.ibef.orgPharmaceuticals7
STRUCTURE OF PHARMA SECTOR IN INDIA
Pharmaceuticals
Source: Dun and Bradstreet
Active Pharmaceutical
Ingredients/ Bulk drugs
Formulations
Branded Generics Branded Generics
Cardiovascular
Anti-Diabetes
Gastro-Intestinal
Neurological
Anti-infectives
Respiratory
Pain
Gynecology
8. For updated information, please visit www.ibef.orgPharmaceuticals8
EVOLUTION OF INDIAN PHARMACEUTICAL SECTOR
Source: Aranca Research
Notes: KAM - Key Account Management, CSO - Contract Sales Organisation
Indian Patent Act passed in 1970
Several domestic companies start
operations
Development of production
infrastructure
Export initiatives taken
Increased patent filings by pharma players
Likely adoption of newer sales models such
as channel management, KAM and CSO
The National Pharmaceutical Pricing Policy,
2012 (NPPP-2012)
In Union Budget, 2016, FDI increased to 74
per cent in existing pharmaceutical
companies
The Government of India unveiled 'Pharma
Vision 2020' aimed at making India a global
leader in end-to-end drug manufacture.
Approval time for new facilities has been
reduced to boost investments.
Liberalised market
Indian companies increasingly launch
operations in foreign countries
India a major destination for generic drug
manufacturing
Approval of Patents (Amendment) Act 2005,
which led to adoption of product patents in
India
2013: New Drug Pricing Control Order issued by Directorate of Food and Drugs this will reduce the
prices of drugs by 80 per cent
2014: 100 per cent FDI allowed in medical device industry. The investment will be routed through
automatic route
Leading Indian pharma companies are raising funds aggressively to fund acquisition in domestic
as well as international market to increase their product portfolios
2015: India has 10,500 manufacturing units and over 3,000 pharma companies
National Health Policy Draft 2015 to increase expenditure in health care sector
Patent Act Amendment 2015, it includes amendments in Patent Act 2002
1990-2010 2010- 20152010
2016
onwards
1970-90
9. For updated information, please visit www.ibef.orgPharmaceuticals9
Important Segments in Indian Pharmaceutical Sector
Active Pharmaceutical Ingredients
(APIs)
Domestic API consumption is expected to reach
US$ 18.8 billion by FY221.
In April 2018, a high-level task force was
constituted to create a roadmap for increasing
domestic production of APIs. Currently India
imports over 60 per cent of its APIs from other
countries.
Contract Research and Manufacturing
Services (CRAMS)
Fragmented market with more than 1,000 players
CRAMS industry is estimated to reach US$ 18
billion in 2018 and expected to witness a strong
growth at a CAGR of 18-20 per cent between
2013-18.
Biosimilar
The government plans to allocate US$ 70 million
for local players to develop Biosimilar.
The domestic market is expected to reach US$ 40
billion by 2030
Formulations
Largest exporter of formulations in terms of
volume, with 14 per cent market share and 12th in
terms of export value. Drug formulation* exports
from India reached US$ 12.91 billion during FY18
and US$ 4.50 billion in April-July 2018.
Double-digit growth is expected over the next five
years
Pharmaceutical
industry
Notes: OTC - Over The Counter,* including biologicals
Source: 1 RNCOS, BMI, Datamonitor, Kemwell Biopharma, Chemical Pharmaceutical Generic Association, ICRA Report estimates, pharmanewsprwire.com, DGCI&S
10. For updated information, please visit www.ibef.orgPharmaceuticals10
INDIAN PHARMA SECTOR REVENUES TRENDING
NORTH
3.14 3.19 3.08
12.32
13.92
14.97
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
20.00
2015 2016 2017
Scheduled Formulations Non-Scheduled Formulations
Source: Department of Pharmaceuticals, PwC, McKinsey, AIOCD AWACS, , IQVIA
Note: F - Forecast, CAGR - Compound Annual Growth Rate, CY – Calendar Year, E - Estimated
Indian pharmaceutical market grew 5.5 per cent in CY2017 in terms
of moving annual turnover. With a turnover of Rs 1.16 trillion (US$
18.06 billion).
In August 2018, the market grew by 8.7 per cent year-on-year with
sales of Rs 11,342 crore (US$ 1.69 billion).
Medicine spending in India is expected to increase at 9-12 per cent
CAGR between 2018-22 to US$ 26-30 billion.
India’s cost of production is significantly lower than that of the US
and almost half of that of Europe. It gives a competitive edge to India
over others.
Increase in the size of middle class households coupled with the
improvement in medical infrastructure and increase in the
penetration of health insurance in the country will also influence in
the growth of pharmaceuticals sector.
Visakhapatnam port traffic (million tonnes)Annual Turnover of Indian Pharmaceutical Market (US$ billion)
15.46
17.11
18.06
11. For updated information, please visit www.ibef.orgPharmaceuticals11
COMPOSITION OF INDIAN PHARMA MARKET
Source: FCCI Indian Pharma Summit, 1KPMG US-India Dynamic June 2018, 2Medicine Man January 2018
1With 70 per cent of market share (in terms of revenues), generic
drugs form the largest segment of the Indian pharmaceutical sector.
Over the Counter (OTC) medicines and patented drugs constitute 21
per cent and 9 per cent, respectively
The share of generic drugs is expected to continue increasing;
domestic generic drug market is expected to reach US$ 27.9 billion
in 2020
Due to their competence in generic drugs, growth in this market
offers a great opportunity for Indian firms
Based on moving annual turnover, Anti-infectives, Cardiac, Gastro
Intestinal had the biggest market share in the Indian pharma market
in 2017.
2.46
2.20
2.09
1.63
1.55
1.34
1.22
1.14
1.09
0.91
0.37
0.34
0.34
0.31
0.22
0.21
0.19
0.10
0.08
0.08
Anti-Infectives
Cardiac
Gastro Intestinal
Anti Diabetic
Vitamins/Minerals/Nutri…
Respiratory
Pain/Analgesics
Derma
Neuro
Gynaecological
Anti-Neoplastics
Vaccines
Opthal/Otologicals
Hormones
Blood Related
Urology
Others
Sex Stimulants…
Stomatologicals
Anti Malarials
Segment Wise Moving Annual Turnover2 December 2017 (US$
billion)
12. For updated information, please visit www.ibef.orgPharmaceuticals12
PHARMA EXPORT TO CONTINUE WITNESSING
POSITIVE GROWTH
38%
20%
12%
30%
USA SSA EU ROW
Source: Department of Commerce India, Department of Pharmaceuticals, India Business News, Global Trade Atlas, KPMG US-India Dynamic June 2018
India is the world’s largest provider of generic medicines; the country’s generic drugs account for 20 per cent of global generic drug exports (in
terms of volumes). Indian drugs are exported to more than 200 countries in the world, with the US as the key market.
Indian pharma companies are capitalising on export opportunities in regulated and semi-regulated markets.
Pharmaceutical exports from India reached US$ 17.27 billion in FY18.
The biggest export destination for Indian pharma product is the US. In 2017, 38 per cent of India’s formulated product exports were to the US,
followed by 20 per cent to sub-Saharan Africa. In FY18, 31 per cent of total pharma exports from India went to the US.
Visakhapatnam port traffic (million tonnes)Export of Formulated Products from India in 2017
10.1
12.6
14.5 14.9
16.9 16.8 17.3
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
16.0
18.0
20.0
FY12 FY13 FY14 FY15 FY16 FY17 FY18
Visakhapatnam port traffic (million tonnes)Pharmaceutical Exports from India(US$ billion)
13. For updated information, please visit www.ibef.orgPharmaceuticals13
PHARMA GIANTS RAISE THEIR R&D SPENDING
361 359
306
174
104 85 62
-
50
100
150
200
250
300
350
400
Sunpharma
Lupin
Dr.Reddy
Cipla
Aurbindo
Cadila
Wockhardt
Source: Company websites, CRISIL Research
Investment (as % of sales) in research & development by Indian pharma companies increased from 5.5 per cent in FY11 to 9 per cent in FY17.
In FY17, highest expenditure on research and development was done by Sun Pharma, followed by Lupin.
Sun Pharma’s R&D spending was 7.6 per cent of the total sales in the FY17 , which grew at a CAGR of 38.3 per cent from FY11 to FY17.
Sun Pharma’s R&D plan includes developing more products through expanded R&D team for global markets, focussing on more complex
products across multiple dosage forms and investments in speciality pipeline
Lupin’s R&D spending was 13.5 per cent of sales in FY17, with major thrust on oral solids (45 per cent of R&D spend)
R&D spending by top six pharma companies FY17 (US$ million)
5.5 5.7 6.0
6.8
7.2
8.1
9.0
-
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
9.0
10.0
FY11 FY12 FY13 FY14 FY15 FY16 FY17
R&D investment by Indian Pharma companies (% of sales)
15. For updated information, please visit www.ibef.orgPharmaceuticals15
Indian pharma companies spend 8-13 per cent of their total turnover on R&D
Expenditure on R&D is likely to increase due to the introduction of product patents; companies need to
develop new drugs to boost sales
India’s pharmaceutical export market is thriving due to strong presence in the generics space
Pharmaceuticals exports from India stood at US$ 17.27 billion in FY18.
Cipla, the largest supplier of anti-malarial drugs to Africa, set up a US$ 32 billion plant in Africa for the
production of anti-retroviral and anti-malarial drugs.
Mankind Pharma is planning to enter the US market and might start product filings in 2018.
Multinational companies are collaborating with Indian pharma firms to develop new drugs
Cipla formed an exclusive partnership with Serum Institute of India to sell vaccines in South Africa
Six leading pharmaceutical companies have formed an alliance ‘LAZOR’ to share their best practices, so as
to improve efficiency and reduce operating costs
NOTABLE TRENDS IN THE INDIAN
PHARMACEUTICALS SECTOR
Source: Aranca Research, Pharmexcil
Notes: R&D - Research and Development
Research and
development
Increasing exports
Expansion by Indian
players abroad
Joint Ventures
16. For updated information, please visit www.ibef.orgPharmaceuticals16
STATES HOSTING KEY PHARMACEUTICAL
VENTURES
Source: Company websites
Wockhardt's facility covers an area of
40,468 sq meters in Baddi, Himachal
Pradesh
Baddi is also home to Cipla’s
formulations manufacturing facility
Piramal’s USFDA-approved
manufacturing plant in Hyderabad
GlaxoSmithKline has a major facility at
Rajahmundry, Andhra Pradesh
Mandideep in Madhya Pradesh is the
manufacturing hub for Lupin’s
cephalosporin and ACE-Inhibitors
Cipla has a formulations manufacturing
plant at Indore
Dholka in Gujarat houses a major
manufacturing facility of Cadila,
which spans over 100 acres
Lupin has an USFDA-approved
plant at Tarapur, Maharashtra. The
facility forms the core of Lupin's
fermentation capabilities
Sun Pharma's API manufacturing
facility at Toansa, Malanpur,
Guwahati, Ankleshwar, Panoli,
Ahmednagar, Maduramthakam
17. For updated information, please visit www.ibef.orgPharmaceuticals17
STRATEGIES ADOPTED
Sun Pharma is trying to achieve cost leadership by
• Vertical Integration: Complex API, which require special skills and technology, are developed and scaled
up for both API and dosage forms
Cost leadership
Source: Company websites, Ministry of External Affairs, RBI
Players in the sector are trying to strengthen their position in the market and expand themselves by investing
heavily in R&D activities, such as:
• Dr Reddy’s acquired OctoPlus N.V, a Netherlands-based company, to get access to the Poly Lactic-Co-
Glycolic Acid (PLGA) technology for the formulation of complex injectables
• In January 2017, Piramal Enterprises acquired a portfolio of anti-spasticity and pain management drugs
from US based drug maker – Mallinckrodt, for US$ 203 million.
• In May 2017, Lupin has launched erectile dysfunction drug named as Cialis. The company has quoted the
market worth for US$ 58.01 million in India. This tablet is available in 20 mg and 10 mg strengths.
Differentiation
Lupin is making inroads into new markets such as Latin America, Russia and other East European countries
Sun Pharma decided to focus on specialty and chronic therapies such as neurology, oncology, dermatology
segments
Companies like Dr Reddy’s, Cipla and Wockhardt are planning their expansions in US$ 100 billion China
market in 2018.
Focus on new markets
Notes: R&D – Research and Development
In October 2016, Advanced Enzyme Technologies, a biotech based firm in Mumbai signed an agreement with
JC Biotech - Active Pharmaceutical Ingredient (API) maker in Hyderabad, to acquire 70 per cent stake in the
company.
In December 2017, Torrent Pharmaceuticals completed acquisition of branded business of Unichem
Laboratories.
Mergers and
Acquisitions in Biotech
19. For updated information, please visit www.ibef.orgPharmaceuticals19
GROWTH DRIVERS OF INDIAN PHARMA SECTOR
Source: Pharmaceutical Export Promotion Council
Notes: BPL - Below Poverty Line, USFDA - United States Food and Drug Administration, NPPP-2012--The National Pharmaceutical Pricing Policy, 2012
Cost advantage
Skilled manpower
India a major manufacturing hub
for generics
India accounts for 22 per cent of
overall USFDA approved plants
Increasing penetration of chemists
Increasing fatal diseases
Accessibility of drugs to greatly
improve
Increasing penetration of health
insurance
Growing number of stress-related
diseases due to change in lifestyle
Better diagnostic facilities
National Health Policy 2015, which focuses on increasing public expenditure on
healthcare segment
Reduction in approval time for new facilities
Plans to set up new pharmaceutical education and research institutes
Exemptions to drugs manufactured through indigenous R&D from price control under
NPPP-2012
Growth Drivers
20. For updated information, please visit www.ibef.orgPharmaceuticals20
SUPPLY-SIDE DRIVERS OF INDIAN PHARMA SECTOR
Following the introduction of product patents, several multinational companies are expected to launch
patented drugs in India
Growth in the number of lifestyle diseases in India could boost the sale of drugs in this segment
High Court allowing to export patent drugs, to foreign players in the Indian market.
Launch of patented
drugs
Source: BMI, India Biz, Nicholas Hall & Company, IQVIA
Pharma companies have increased spending to tap rural markets and develop better medical infrastructure
Hospitals’ market size is expected to increase by US$ 200 billion by 2024
Medical devices industry in India has been growing 17 per cent annually and was valued at US$ 4.9 billion in
2017.
Medical infrastructure
About 120 drugs are expected to go off-patent over the next 10 years; with expected worldwide revenue
between US$ 80 to 250 billion
Patent Expiry
Notes: CAGR - Compound Annual Growth Rate
India’s generic drugs account for 20 per cent of global exports in terms of volume, making it country the largest
provider of generic medicines globally. The generics drug market accounts for around 70 per cent of the India
pharmaceutical industry and it is expected to reach US$ 27.9 billion by 2020
Scope in generics
market
India’s OTC drugs market is estimated to have grown at a CAGR of 16.3 per cent to US$ 6.6 billion over
2008–16 and is further expected to grow on the account of increased penetration of chemists, especially in
rural regions. Indian OTC market is expected to grow at a CAGR of 9 per cent from 2016-26 to cross Rs
44,115 crore (US$ 6.81 billion).
Over-The-Counter
(OTC) drugs
21. For updated information, please visit www.ibef.orgPharmaceuticals21
DEMAND DRIVERS OF INDIAN PHARMA SECTOR
Accessibility
Over US$ 200 billion to be spent on medical
infrastructure in the next decade
New business models expected to penetrate tier-2 and 3
cities
Over 160,000 hospital beds expected to be added each
year in the next decade
India’s generic drugs account for 20 per cent of global
exports in terms of volume, making the country the
largest provider of generic medicines globally
Acceptability
Rising levels of education to increase acceptability of
pharmaceuticals
Patients to show greater propensity to self-medicate,
boosting the OTC market
Acceptance of biologics and preventive medicines to
rise
A skilled workforce as well as high managerial and
technical competence
Surge in medical tourism due to increased patient
inflow from other countries
Epidemiological factors
Patient pool expected to increase over 20 per cent in
the next 10 years, mainly due to rise in population
New diseases and lifestyle changes to boost demand
Increasing prevalence of lifestyle diseases
Affordability
Rising income could drive 73 million households to the
middle class over the next 10 years
Over 650 million people expected to be covered by
health insurance by 2020
Government-sponsored programmes set to provide
health benefits to over 380 million BPL people by the
end of 2017
The government plans to provide free generic
medicines to half the population at an estimated cost of
US$ 5.4 billion
Demand
drivers
Source: ICRA Report on Indian Pharmaceutical Sector, Pharmaceutical Industry: Developments in India- Deloitte, Mckinsey Pharma Report 2020
Note: RSBY - Rashtriya Swasthya Bima Yojna
22. For updated information, please visit www.ibef.orgPharmaceuticals22
GROWING HEALTH INSURANCE
Source: IRDA, General Insurance Council
Increasing penetration of non-life insurance including health insurance will drive the expansion of healthcare services and pharmaceutical market
in India.
Adoption of health insurance in the country has been increasing at a fast pace.
Gross direct premium from health insurance reached Rs 378.97 billion (US$ 5.88 billion) in FY18 and contributed 25.2 per cent to the gross direct
premiums of non-life insurance companies in India. In FY19 (up to July 2018) premiums increased 18.7 per cent year-on-year to Rs 14,278.76
crore (US$ 2.13 billion).
Another boost to the sector will be the National Health Protection Scheme under Ayushman Bharat, announced in Union Budget 2018-19. The
scheme will be launched on September 25, 2018.
9.28
11.05
12.03
13.14
14.95
19.89
23.38
0.00
5.00
10.00
15.00
20.00
25.00
FY12
FY13
FY14
FY15
FY16
FY17
FY18
CAGR 16.65%
Gross Direct Premiums of Non-Life Insurers (US$ billion)Visakhapatnam port traffic (million tonnes)Break-up of non-life insurance market in India (FY18)
25.20%
74.8%
Health Others
Total size:
US$ 23.38
billion
23. For updated information, please visit www.ibef.orgPharmaceuticals23
FAVOURABLE POLICY MEASURES SUPPORT
GROWTH (1/2)
Steps taken to reduce approval time for new facilities
NOC for export licence issued in two weeks compared to 12 weeks earlier
Reduction in approval
time for new facilities
Government is planning to relax FDI norms in the pharmaceutical sector
In March 2017, the government decided to create a digital platform to regulate and track the sale of quality
drugs, and it can be used by people living in the country as well as abroad
Support for technology
upgrades and FDIs
Pharma Vision 2020 by the government’s Department of Pharmaceuticals aims to make India a major hub for
end-to-end drug discovery
Pharma Vision 2020
As per NBDS, a proposal has been made to set up the National Biotechnology Regulatory Authority (NBRA) to
provide a single-window clearance mechanism for all bio-safety products to create efficiencies & streamline
the drug approval process
Single-window
clearance
Government of India is planning to set up mega bulk drug parks in order to reduce industry’s dependency on
raw material imports.
Bulk Drug Parks
Government of India is planning to set up an electronic platform to regulate online pharmacies under a new
policy
Online Pharmacies
The Industry – Academia mission was launched in June 2017 to boost development of biopharmaceuticals in
India.
National Biopharma
Mission
24. For updated information, please visit www.ibef.orgPharmaceuticals24
FAVOURABLE POLICY MEASURES SUPPORT
GROWTH (2/2)
Source: Livemint, Union Budget
The allocation to the Ministry of Health and Family Welfare has increased by 11.5 per cent to Rs 52,800 crore
(US$ 8.16 billion).
The National Health Protection Scheme is largest government funded healthcare programme in the world,
which is expected to benefit 100 million poor families in the country by providing a cover of up to Rs 5 lakh
(US$ 7,723.2) per family per year for secondary and tertiary care hospitalisation.
The government has allocated Rs 1,200 crore (US$ 185.36 million) towards the National Health Policy 2017
under which 150,000 health and wellness centres, will provide healthcare closer to homes of the people.
The increased expenditure on healthcare is expected to benefit the pharmaceutical sector as well
Union Budget 2018-19
BIRAC has been established to promote research & innovation capabilities in India’s biotech industry. The
council will provide funding to biotech companies for technology & product development.
BIRAC under Small Business Innovation Research Initiative (SBIRI) scheme supports innovations in
biotechnology.
Biotechnology Industry
Research Assistance
Council
Programme on application of biotechnology for women was done to provide employment, skill development,
awareness generation, health improvement & socio-economic upliftment of the women population
Biotechnology Based
Programme for Women
25. For updated information, please visit www.ibef.orgPharmaceuticals25
NATIONAL PHARMA POLICY TO BRING GREATER
TRANSPARENCY
In 2017, the Department of Pharmaceuticals released a draft National Pharmaceutical Policy with the following objectives:
• Make all essential drugs accessible to masses through affordable prices
• Provide the Indian pharmaceutical sector with a long term stable policy environment
• Make India self sufficient in end to end domestic drug manufacturing
• Maintain world class quality for domestic consumption and exports
• Create a positive environment for research and development in the pharma sector.
As per the new policy, the Department of Pharmaceuticals will have control over the National List of Essential Medicines (NLEM), which decides
the drugs for which the Government of India can control the prices.
26. For updated information, please visit www.ibef.orgPharmaceuticals26
GOVERNMENT EXPENDITURE IN THE PHARMA
SECTOR ON AN UPTREND
19.55
21.57
23.12 23.58
35.07 34.91
0.00
5.00
10.00
15.00
20.00
25.00
30.00
35.00
40.00
FY13 FY14 FY15 FY16 FY17 FY18
Source: Business Monitor International, Economic Survey 2017-18
Note: CAGR - Compound Annual Growth Rate
Government expenditure on health increased from Rs 1.26 lakh crore
(US$ 19.55 billion) in FY12 to Rs 2.25 lakh crore (US$ 34.91 billion)
in FY18, implying a CAGR of 12.3 per cent.
Medical technology park in Vishakhapatnam, Andhra Pradesh has
already been set up with an investment of US$ 183.31 million. States
like Himachal Pradesh, Gujarat, Telangana and Maharashtra are
showing interest for making investments in these parks.
German technical services provider TUV Rheinland’s Indian
subsidiary has partnered with Andhra Pradesh MedTech Zone
(AMTZ) to create an infrastructure for Electro-Magnetic Interference
(EMI/EMC) at an investment of US$ 12.64 million over a course of
four to five years.
Visakhapatnam port traffic (million tonnes)Government Expenditure on Health in India (US$ billion)
27. For updated information, please visit www.ibef.orgPharmaceuticals27
INVESTMENTS, JVs INFUSING SUPERIOR
CAPABILITIES IN INDIAN FIRMS
Source: BMI, Business Standard
Date Announced Indian company Foreign company Value (US$ million) Type
December 2017 Unichem Laboratories Torrent Pharma NA Acquisition
March, 2017 Sun Pharma Thallion Pharmaceuticals 19.77 Acquisition
January, 2017 Zydus Cadila Zoetis NA Acquisition
February 2017 Piramal Mallinckrodt 170 Specialty products
July 2016 Continental Hospitals Ltd. HH Healthcare Berhad 192.84 73.4% Stake
February 2016 Cipla
InvaGen Pharmaceuticals Inc. and
Exelan Pharmaceuticals Inc.
550 100% Stake
November 2015 Famy Care Ltd
Mylan Inc – Mylan Laboratories
Limited
750 100% Stake
October 2015 Nitin Lifesciences Recipharm 109.8 75% stakes in equity
July 2015 Lupin Temmler Not disclosed Acquisition
May 2015 Cadila Healthcare Claris Lifesciences 556.8 To be acquired
July 2015 Lupin Gavis and Novel Laboratories 880 Acquisition
April 2014 Sun Pharma Ranbaxy 320 Acquisition
November, 2014 Curatio Healthcare Sequoia Capital 15.8 Acquisition
July, 2013 Cipla Cipla Medpro 512 Acquisition
January, 2013 GlaxoSmithkLine Consumer GlaxoSmithkLine Plc. 1,088 Acquisition
Indian Drugs & Pharmaceuticals sector has received cumulative FDI worth US$ 15.83 billion between April 2000 and June 2018.
During April-June 2018, pharmaceutical sector in India witnessed private equity and venture capital investments of US$ 396 million.
In 2017, Indian pharmaceutical sector witnessed 46 merger & acquisition (M&A) deals worth US$ 1.47 billion.
Over the last three years, pharmaceuticals segment has accounted for more than 70 per cent of M&A deals.
Note: JV - Joint Venture
29. For updated information, please visit www.ibef.orgPharmaceuticals29
OPPORTUNITIES ABOUND IN CLINICAL TRIALS AND
HIGH-END DRUGS
India is among the leaders
in the clinical trial market
Due to a genetically diverse
population and availability of
skilled doctors, India has
the potential to attract huge
investments to its clinical
trial market
Number of clinical trials in
India increased by 400 per
cent to 97 in 2017,
compared with 13 trials
approved in 2013.
Clinical trials market
Due to increasing
population and income
levels, demand for high-end
drugs is expected to rise
Growing demand could
open up the market for
production of high-end
drugs in India
High-end drugs
With 70 per cent of India’s
population residing in rural
areas, pharma companies
have immense opportunities
to tap this market
Demand for generic
medicines in rural markets
has seen a sharp growth.
Various companies are
investing in the distribution
network in rural areas
Penetration in rural market
The Contract Research and
Manufacturing Services
industry (CRAMS) –
estimated at US$ 9.3 billion
in 2014, is expected to
reach US$ 19 billion by
2018.
The market has more than
1,000 players
CRAMS
Source: BMI, Drug Controller General of India
31. For updated information, please visit www.ibef.orgPharmaceuticals31
INDUSTRY ORGANISATIONS
Address: Kalina, Santacruz (E),
Mumbai – 400 098
Phone: 91-22-2667 1072
Fax: 91 22 2667 0744
E-mail: ipacentre@ipapharma.org
www.ipapharma.org
The Indian Pharmaceutical Association
Address: 102-B, Poonam Chambers, Dr A.B. Road
Worli, Mumbai – 400 018
Phone: 91-22-2494 4624/2497 4308
Fax: 9122 24950723
E-mail: idma1@idmaindia.com
www.idma-assn.org
Indian Drug Manufacturers' Association
Address: Peninsula Chambers, Ground Floor,
Ganpatrao Kadam Marg, Lower Parel,
Mumbai – 400 013
Phone: 9122 24918123, 24912486, 66627007
Fax: 9122 24915168
E-mail: indiaoppi@vsnl.com
www.indiaoppi.com
Organisation of Pharmaceutical Producers of India
Address: C-25, Industrial Estate, Sanath Nagar
Hyderabad – 500018
Phone: 91 40 23703910/23706718
Fax: 91 40 23704804
E-mail: info@bdmai.org
www.bdmai.org
Bulk Drug Manufacturers Association
32. For updated information, please visit www.ibef.orgPharmaceuticals32
GLOSSARY
CRAMS: Contract Research and Manufacturing Services
API: Active Pharmaceutical Ingredients
FDI: Foreign Direct Investment
GOI: Government of India
INR: Indian Rupee
US$ : US Dollar
BPL: Below Poverty Line
RSBY: Rashtriya Swastha Bima Yojna
ESIC: Employees State Insurance Corporation
Wherever applicable, numbers have been rounded off to the nearest whole number
33. For updated information, please visit www.ibef.orgPharmaceuticals33
EXCHANGE RATES
Exchange Rates (Fiscal Year) Exchange Rates (Calendar Year)
Year INR INR Equivalent of one US$
2004–05 44.95
2005–06 44.28
2006–07 45.29
2007–08 40.24
2008–09 45.91
2009–10 47.42
2010–11 45.58
2011–12 47.95
2012–13 54.45
2013–14 60.50
2014-15 61.15
2015-16 65.46
2016-17 67.09
2017-18 64.45
Q1 2018-19 67.04
Year INR Equivalent of one US$
2005 44.11
2006 45.33
2007 41.29
2008 43.42
2009 48.35
2010 45.74
2011 46.67
2012 53.49
2013 58.63
2014 61.03
2015 64.15
2016 67.21
2017 65.12
Source: Reserve Bank of India, Average for the year
34. For updated information, please visit www.ibef.orgPharmaceuticals34
DISCLAIMER
India Brand Equity Foundation (IBEF) engaged Aranca to prepare this presentation and the same has been prepared by Aranca in consultation
with IBEF.
All rights reserved. All copyright in this presentation and related works is solely and exclusively owned by IBEF. The same may not be reproduced,
wholly or in part in any material form (including photocopying or storing it in any medium by electronic means and whether or not transiently or
incidentally to some other use of this presentation), modified or in any manner communicated to any third party except with the written approval
of IBEF.
This presentation is for information purposes only. While due care has been taken during the compilation of this presentation to ensure that the
information is accurate to the best of Aranca and IBEF’s knowledge and belief, the content is not to be construed in any manner whatsoever as a
substitute for professional advice.
Aranca and IBEF neither recommend nor endorse any specific products or services that may have been mentioned in this presentation and nor do
they assume any liability or responsibility for the outcome of decisions taken as a result of any reliance placed on this presentation.
Neither Aranca nor IBEF shall be liable for any direct or indirect damages that may arise due to any act or omission on the part of the user due to any
reliance placed or guidance taken from any portion of this presentation.